Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (LGND) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · LGND · as of Mar 31, 2025
Ownership Breakdown
265
Institutional Holders
$1.97B
Total Inst. Value
▲ $16.00M vs Q4
20.04M
Shares Outstanding
freeFloat 97.60%
18.73M
13F Shares Held
▲ 476,028 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
LGND largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. pharmaceutical preparations | 2.92M | 15.22% | 15.22% | $307.03B | May 2, 2025 | ▼ 25.8K |
VANGUARD GROUP INC pharmaceutical preparations | 2.06M | 10.71% | 10.71% | $216.14B | May 9, 2025 | ▼ 29.9K |
JANUS HENDERSON GROUP PLC pharmaceutical preparations | 1.03M | 5.35% | 5.35% | $110.58B | May 15, 2025 | ▲ 12.5K |
MACQUARIE GROUP LTD pharmaceutical preparations | 906.2K | 4.72% | 4.72% | $95.28B | Aug 14, 2025 | ▲ 21.8K |
DIMENSIONAL FUND ADVISORS LP pharmaceutical preparations | 744.9K | 3.88% | 3.88% | $78.32B | May 13, 2025 | ▲ 21.9K |
STATE STREET CORP pharmaceutical preparations | 727.1K | 3.79% | 3.79% | $76.45B | May 15, 2025 | ▼ 16.5K |
CONGRESS ASSET MANAGEMENT CO /MA pharmaceutical preparations | 642.7K | 3.35% | 3.35% | $67.57B | Apr 11, 2025 | ▲ 21.2K |
STEPHENS INVESTMENT MANAGEMENT GROUP LLC pharmaceutical preparations | 607.2K | 3.16% | 3.16% | $63.84B | May 1, 2025 | ▼ 5.6K |
CHICAGO CAPITAL, LLC pharmaceutical preparations | 554.5K | 2.89% | 2.89% | $58.30B | Apr 17, 2025 | ▲ 2.9K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 464.5K | 2.42% | 2.42% | $48.84B | May 13, 2025 | ▲ 26.0K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
30
Increased
+574.0K shares1
New Positions
first time holders17
Decreased
−162.1K shares0
Sold Out
fully exitedNet shares change (top 50)
+411.9K
+574.0K / −162.1K
Net new holders
+14
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
LGND insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
39
Sell transactions
0.18
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 491 | $223.95 | $110.0K | 45.9K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 677 | $225.20 | $152.5K | 45.2K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 1,432 | $225.97 | $323.6K | 43.8K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 400 | $226.78 | $90.7K | 43.4K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 584 | $228.57 | $133.5K | 42.8K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 1,216 | $229.47 | $279.0K | 41.6K | Form 4 ↗ |
Reardon Andrew CLO & Secretary | Jun 1, 2026 | Sale | 200 | $230.41 | $46.1K | 41.4K | Form 4 ↗ |
KOZARICH JOHN W director | May 1, 2026 | Sale | 80 | $227.37 | $18.2K | 42.2K | Form 4 ↗ |
KOZARICH JOHN W director | May 1, 2026 | Sale | 1 | $229.87 | $229.87 | 42.2K | Form 4 ↗ |
KOZARICH JOHN W director | May 1, 2026 | Sale | 165 | $231.87 | $38.3K | 42.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Ligand Pharmaceuticals Incorporated (LGND) is primarily owned by institutional investors, who hold approximately 93.4% of total shares outstanding. Company insiders own approximately 2.40%, while retail and public investors account for the remaining 4.17%.
The largest institutional shareholder of Ligand Pharmaceuticals Incorporated is BLACKROCK, INC., holding approximately 2.92 million shares — equal to 15.22% of outstanding shares — as of March 31, 2025.
A total of 265 institutional investors currently hold LGND stock, with a combined institutional value of approximately $1.97 billion as of the most recent 13F filing period.
Frequently asked questions
LGND ownershipLigand Pharmaceuticals Incorporated (LGND) is primarily owned by institutional investors, who hold approximately 93.4% of shares. The largest shareholder is BLACKROCK, INC. with a 15.22% stake. Company insiders hold 2.40%. Data sourced from SEC Form 13F as of March 31, 2025.